--- title: "Impact BioMedical (IBO) news: reverse merger" url: "https://aibio.space/companies/impact-biomedical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IBO reverse merger news: Impact BioMedical signs reverse merger agreement with Dr Ashleys Limited. Impact BioMedical Inc. (AMEX: IBO), United States." --- IBO Impact BioMedical Inc. AMEX · United States # Impact BioMedical (IBO) news IBO reverse merger news Mergers · 2026-09-17 ## [Impact BioMedical reports Zoar F-4 filing in business combination](https://aibio.space/news/impact-biomedical-reports-zoar-f-4-filing-business-combination/) Zoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited. ## Latest Impact BioMedical news 1. 2025-06-23 Mergers [Impact BioMedical signs reverse merger agreement with Dr Ashleys Limited](https://aibio.space/news/impact-biomedical-signs-reverse-merger-agreement-dr-ashleys-limited/) Impact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals. 2. 2025-06-23 Mergers [Impact BioMedical agrees to reverse merger with Hong Kong drugmaker Dr Ashleys](https://aibio.space/news/impact-biomedical-agrees-reverse-merger-hong-kong-drugmaker-dr-ashleys/) The combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval. ## Impact BioMedical at a glance - **Ticker**: IBO - **Listing**: AMEX - **Country**: United States - **Cash, Mar 31, 2026**: $20,000 ### Related companies - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) NASDAQ: BRTX - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) NASDAQ: CELZ - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Dyadic International](https://aibio.space/companies/dyadic-international/) NASDAQ: DYAI - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) NASDAQ: CRDF ### Also on AMEX - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) SER - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) NSRX - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) PTHS - [OS Therapies](https://aibio.space/companies/os-therapies/) OSTX ## What Impact BioMedical does Impact BioMedical Inc. discovers, confirms and patents science and technologies that partners can develop into healthcare and wellness offerings through licensing, co-development, joint ventures and other relationships. It trades on the NYSE American. Its principal subsidiaries include Impact BioLife Science, Inc., Global BioMedical, Inc., Global BioLife, Inc. and Sweet Sense, Inc. Its Linebacker platform is a family of small molecule polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders and neurology, and Linebacker-1 and Linebacker-2 have been licensed to ProPhase Laboratories (NASDAQ: PRPH). Laetose is a patented formulation that the company says could reduce caloric intake and glycemic index in foods, and it is seeking partners for it. Functional Fragrance Formulation (3F) is a suite of fragrances with botanical ingredients, developed with Chemia Corporation of St. Louis, MO. Equivir is a polyphenol blend with potential antiviral effects, also licensed to ProPhase Laboratories for over-the-counter upper respiratory wellness. The company reports sixty (60) issued and over sixty (60) pending patents at the end of 2025. | Product or program | What it is | Stage | |---|---|---| | Linebacker | Small molecule polyphenol platform for oncology, inflammatory disorders and neurology | | | Laetose | Patented formulation said to reduce caloric intake and glycemic index in foods | Composition patent allowed in the United States | | Functional Fragrance Formulation (3F) | Suite of functional fragrances with botanical ingredients, partnered with Chemia | Composition patents issued in the U.S.; pending in other countries | | Equivir | Polyphenol blend with antiviral effects, licensed to ProPhase Laboratories | | Summarised from the company's [10-K filed Mar 11, 2026](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/form10-k.htm). ## Impact BioMedical annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$32,000](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | | | Research and development | [$340,000](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | [$278,000](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | | Net income (loss) | [-$11.8 million](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | [-$24.7 million](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | | Cash from operations | [-$1.9 million](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | [-$2.9 million](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | | Cash and equivalents | [$3,000](https://www.sec.gov/Archives/edgar/data/1834105/000149315226022512/) | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $20,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Impact BioMedical Is Impact BioMedical doing a reverse merger? Our latest story on this, dated Jun 23, 2025: "Impact BioMedical signs reverse merger agreement with Dr Ashleys Limited". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/impact-biomedical-signs-reverse-merger-agreement-dr-ashleys-limited/). What is the ticker symbol of Impact BioMedical? Impact BioMedical Inc. trades under the ticker IBO on AMEX. Where is Impact BioMedical listed? Impact BioMedical Inc. is listed on AMEX. What is the SEC CIK of Impact BioMedical? The SEC Central Index Key (CIK) for Impact BioMedical Inc. is 1834105. Its filings are on SEC EDGAR. How many shares does Impact BioMedical have outstanding? 107,821,231 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Impact BioMedical listed under? Our directory records Impact BioMedical Inc. under United States. What does Impact BioMedical do? Our directory classifies Impact BioMedical Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Impact BioMedical? The ISIN recorded for Impact BioMedical Inc. is US45259L3042. Does aibio.space cover Impact BioMedical? aibio.space lists Impact BioMedical Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Impact BioMedical incorporated? SEC records list its state or country of incorporation as NV. What does Impact BioMedical develop? Impact BioMedical Inc. discovers, confirms and patents science and technologies that partners can develop into healthcare and wellness offerings through licensing, co-development, joint ventures and other relationships. It trades on the NYSE American. What is Linebacker from Impact BioMedical? Linebacker: Small molecule polyphenol platform for oncology, inflammatory disorders and neurology Stage: Not stated in text. What is Laetose from Impact BioMedical? Laetose: Patented formulation said to reduce caloric intake and glycemic index in foods Stage: Composition patent allowed in the United States. What was Impact BioMedical's revenue last year? $32,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Impact BioMedical profitable? Impact BioMedical Inc. reported a net loss of $11.8 million for the fiscal year ended Dec 31, 2025, and used $1.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Impact BioMedical Members talk about Impact BioMedical (IBO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Impact BioMedical, newest first. Each line links the filing it comes from. 1. 2026-10-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/form8-k.htm) 2. 2026-09-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/ex99-1.htm) 3. 2026-09-15 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042640/form425.htm) 4. 2025-06-23 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:IBO on TradingView](https://www.tradingview.com/symbols/AMEX-IBO/). ## SEC filings and registration - **SEC name**: Impact Biomedical Inc. - **CIK**: 1834105 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IBO (NYSE) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 275 WIREGRASS PKWY,, WEST HENRIETTA, NY, 14586 - **Phone**: 585 232 1500 - **Shares outstanding**: 107,821,231 as of 2026-08-04 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/form8-k.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042975/form8-k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/form8-k.htm) filed 2026-09-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1834105/000149315226036601/form10-q.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1834105/000149315226022512/form10-q.htm) filed 2026-05-12 - [10-K](https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/form10-k.htm) filed 2026-03-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1834105/000149315226008879/form8-k.htm) filed 2026-03-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1834105/000149315225021286/form10-q.htm) filed 2025-11-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001834105), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Impact BioMedical Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker IBO, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Impact BioMedical Inc. - **Ticker**: IBO - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US45259L3042 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-IBO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/impact-biomedical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Impact BioMedical (IBO) news: reverse merger", 2026-10-31, https://aibio.space/companies/impact-biomedical/